Format

Send to

Choose Destination
Rinsho Ketsueki. 2018;59(10):2089-2093. doi: 10.11406/rinketsu.59.2089.

[Adverse events of ABL tyrosine kinase inhibitors in chronic myeloid leukemia therapy].

[Article in Japanese]

Author information

1
Department of Hematology, Tokyo Medical University.

Abstract

Fatal events during treatment with ABL tyrosine kinase inhibitors (ABL TKIs) have been reported, and there have been concerns of high mortality rate in patients with chronic myeloid leukemia receiving ABL TKIs. The predictive factors of patients treated with ABL TKIs who are at risk of potentially fatal toxicities remain unknown. Although this scenario appears discouraging, the risk of severe toxicity might be predicted by investigating the effect of genetic variation on the disposition of ABL TKIs. Global genomic surveys should be conducted to identify factors contributing to an increased risk of toxicity using multivariable analyses with particular reference to ABL TKIs pharmacokinetics and baseline clinical characteristics.

KEYWORDS:

ABL kinase inhibitor; Adverse events; BCR-ABL1

PMID:
30305513
DOI:
10.11406/rinketsu.59.2089

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic
Loading ...
Support Center